Jmh. Hendriks et al., Isolated lung perfusion with melphalan prolongs survival in a rat model ofmetastatic pulmonary adenocarcinoma, EUR SURG RE, 31(3), 1999, pp. 267-271
Introduction: Survival after isolated lung perfusion (ILuP) with melphalan
was tested in a model of unilateral pulmonary adenocarcinoma. Methods: On d
ay 0, rats were randomized into four groups: Group 1 (n = 9) reveived tumor
cells intravenously for induction of bilateral lung metastases, whereas gr
oups 2-4 (n = 21) underwent a 10-min occlusion of the right pulmonary arter
y during tumor cell injection for induction of unilateral left lung metasta
ses. On day 7, groups 1 and 2 received no treatment. Group 3 underwent left
ILuP with melphalan (2.0 mg/kg) while group 4 received melphalan intraveno
usly (0.5 mg/kg). The end point of the study was death from metastatic dise
ase. Results: Median survival of ILuP-treated animals (81 +/- 12 days) was
significantly longer compared to group 1 (18 +/- 1 days; p = 0.0001), group
2 (28 +/- 3 days; p = 0.0002) and group 4 (37 +/- 6; p = 0.0004). Conclusi
ons: ILuP with melphalan prolongs survival in the treatment of experimental
metastatic pulmonary carcinoma.